Introduction and Overview

  • Evelyn WalterEmail author
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 213)


The overall aim of this book is to set out the main changes needed in the field of economic and regulatory conditions as a consequence of these rapid developments in oncology. The traditional approaches of health economics, like health economic evaluation, health technology assessment (HTA), modeling methods, assessing value, pricing techniques, are bound to be altered in the contributions to this book. It is understandable that with the life-threatening diagnosis of cancer the new treatment options need to be accompanied by the best available health economic tools. This pertains to well-implemented decision rules concerning willingness to pay, incremental cost-effectiveness ratio thresholds, equity, patient access, end of life criteria, etc. Their application differs with regard to the usual health economic analyzes implemented in other treatment areas. Overstating a bit one could ask whether we need a strongly modified concept of oncology economics?


Cancer incidence Oncology cone Prices of cancer medication 


  1. IQVIA Institute (2018). Accessed 15 June 2018
  2. Kleinrock M (2015) Oncology innovation and challenging choices: balancing value and funding priorities in light of an abundance of new treatment options. Am Health Drug Benefits 8(4):196–199PubMedPubMedCentralGoogle Scholar
  3. Miller JD, Foley KA, Russell MW (2014) Current challenges in health economic modeling of cancer therapies: a research inquiry. Am Health Drug Benefits 7(3):153–162PubMedPubMedCentralGoogle Scholar
  4. Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A (2017) Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open (2018 Feb) 2;3(2):e000285. (eCollection 2018)CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Institute for Pharmaeconomic ResearchViennaAustria

Personalised recommendations